Defitelio defibrotide regulatory update

Jazz began a rolling NDA submission to FDA for defibrotide to treat severe hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. The company expects to complete the submission this half and request Priority Review for the application. ...